Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583845 | 0.88 | ADRB3 (0.43) | BACE1ADRB3KDM4EALDH1A1ADRB1 | |
| SCHEMBL4583840 | 0.88 | ADRB3 (0.43) | BACE1ADRB3KDM4EALDH1A1ADRB1 | |
| SCHEMBL4585455 | 0.87 | ADRB3 (0.52) | BACE1ADRB3KDM4EALDH1A1ADRB1 | |
| SCHEMBL4585450 | 0.87 | ADRB3 (0.52) | BACE1ADRB3KDM4EALDH1A1ADRB1 | |
| SCHEMBL4583941 | 0.87 | BACE1 (0.43) | BACE1ADRB3KDM4EALDH1A1ADRB1 | |
| SCHEMBL4583939 | 0.87 | BACE1 (0.43) | BACE1ADRB3KDM4EALDH1A1ADRB1 | |
| SCHEMBL4584774 | 0.87 | ADRB3 (0.54) | BACE1ADRB3ADRB1 | |
| SCHEMBL4584779 | 0.87 | ADRB3 (0.54) | BACE1ADRB3ADRB1 | |
| SCHEMBL4583226 | 0.86 | ADRB3 (0.42) | BACE1ADRB3KDM4EALDH1A1ADRB1 | |
| SCHEMBL4460208 | 0.86 | ADRB3 (0.54) | BACE1ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | BACE1 3089/4885ADRB3 86/4885KDM4E 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.